<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment of myoclonus
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment of myoclonus
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment of myoclonus
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John N Caviness, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Howard I Hurtig, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            April F Eichler, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 17, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Myoclonus is a sudden, involuntary, shock-like movement caused by sudden muscular contraction (positive myoclonus) or inhibition (negative myoclonus). Among movement disorder phenotypes, myoclonus is the most transient: it is essentially the quickest abnormal movement with a given body part.
        </p>
        <p>
         Myoclonic movements have many possible etiologies, and treatment is generally guided by the anatomic/physiologic type of myoclonus. Although there are some treatable underlying etiologies, myoclonus management is primarily symptomatic, and medications often have limited benefits.
        </p>
        <p>
         This topic will review the treatment of myoclonus. The evaluation, classification, and etiologies of myoclonus are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/4885.html" rel="external">
          "Classification and evaluation of myoclonus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4884.html" rel="external">
          "Symptomatic (secondary) myoclonus"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          GENERAL PRINCIPLES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical sign of myoclonus is uniform, but different distributions occur, and there are myriad etiologies  (
         <a class="graphic graphic_table graphicRef78331" href="/z/d/graphic/78331.html" rel="external">
          table 1
         </a>
         ) and multiple anatomic/physiologic types  (
         <a class="graphic graphic_table graphicRef62397" href="/z/d/graphic/62397.html" rel="external">
          table 2
         </a>
         ). Both elements of classification help to guide therapy.
        </p>
        <p class="headingAnchor" id="H3046318280">
         <span class="h2">
          Treat the underlying disorder
         </span>
         <span class="headingEndMark">
          —
         </span>
         When the etiology of myoclonus is treatable or reversible, treatment of the underlying condition may partially or completely relieve the myoclonus. Examples include myoclonus caused by an acquired abnormal metabolic state (eg, hepatic failure), a removable medication or toxin (eg, selective serotonin reuptake inhibitors, opioids), an excisable lesion (eg, thoracic meningioma for spinal myoclonus), or functional myoclonus.
        </p>
        <p>
         The myoclonus that occurs in certain noninfectious inflammatory syndromes may respond to immunomodulatory treatments such as high-dose glucocorticoids, intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         , monoclonal antibodies, and plasmapheresis. Such treatment is often attempted in inflammatory/autoimmune conditions, with or without an antibody identified. These disorders and their treatments, which are discussed separately, include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autoimmune encephalitis of paraneoplastic and nonparaneoplastic origin, including progressive encephalomyelitis with rigidity and myoclonus (PERM) (see
         <a class="medical medical_review" href="/z/d/html/15759.html" rel="external">
          "Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis", section on 'Anti-GlyR encephalopathy'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sydenham chorea (see
         <a class="medical medical_review" href="/z/d/html/6228.html" rel="external">
          "Sydenham chorea", section on 'Treatment'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Opsoclonus-myoclonus syndrome (see
         <a class="medical medical_review" href="/z/d/html/15861.html" rel="external">
          "Opsoclonus-myoclonus-ataxia syndrome"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Systemic lupus erythematosus (see
         <a class="medical medical_review" href="/z/d/html/4863.html" rel="external">
          "Neurologic and neuropsychiatric manifestations of systemic lupus erythematosus", section on 'Chorea'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Primary antiphospholipid syndrome (see
         <a class="medical medical_review" href="/z/d/html/4682.html" rel="external">
          "Management of antiphospholipid syndrome"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Celiac disease and gluten sensitivity (see
         <a class="medical medical_review" href="/z/d/html/5907.html" rel="external">
          "Management of celiac disease in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4777.html" rel="external">
          "Management of celiac disease in adults"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pediatric autoimmune neuropsychiatric disorder associated with group A streptococci (PANDAS) (see
         <a class="medical medical_review" href="/z/d/html/6031.html" rel="external">
          "PANDAS: Pediatric autoimmune neuropsychiatric disorder associated with group A streptococci"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2065058466">
         <span class="h2">
          Assess need for symptomatic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         With most types of myoclonus, treatment of the underlying disorder is impossible or ineffective. In these cases, symptomatic treatment is indicated for patients with significant disability related to the myoclonus, whether physical or social, or when myoclonus causes high levels of distress for family and caretakers. Physiologic myoclonus (myoclonus during sleep that worries the bed partner only) almost never needs to be treated.
        </p>
        <p>
         There are no highly effective medications for myoclonus, and some therapies may worsen cognitive status or coordination of movements [
         <a href="#rid1">
          1,2
         </a>
         ]. Therefore, decisions about symptomatic treatment always weigh the risks of medication side effects with the potential benefits in terms of symptom severity and quality of life.
        </p>
        <p>
         It is important to review goals and expectations prior to starting symptomatic therapy. High expectations for a marked decrease or total elimination of myoclonus are usually unrealistic. In addition, multiple medication trials are sometimes necessary to find the best drug or drug combination to control myoclonus.
        </p>
        <p class="headingAnchor" id="H1051664189">
         <span class="h2">
          Choose therapy based on physiology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Symptomatic treatment of myoclonus is guided by the anatomic/physiologic type, of which there are five major groups: cortical, cortical-subcortical, subcortical-nonsegmental, segmental, and peripheral  (
         <a class="graphic graphic_table graphicRef62397" href="/z/d/graphic/62397.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4885.html" rel="external">
          "Classification and evaluation of myoclonus", section on 'Anatomic and physiologic classification'
         </a>
         .)
        </p>
        <p>
         This strategy is based upon the premise that an agent or treatment that is effective for one type of myoclonus is likely to be effective for other causes of myoclonus that share the same underlying physiologic mechanism. Furthermore, an agent or treatment that is effective for one physiologic type of myoclonus may be less effective or ineffective for another physiologic type or may even cause worsening.
        </p>
        <p>
         Some clinical phenotypes of myoclonus have more than one potential physiologic mechanism. In cases when the myoclonus physiologic classification cannot be determined, presuming the myoclonus physiology that usually occurs in that diagnosis is a reasonable way to proceed  (
         <a class="graphic graphic_table graphicRef51170" href="/z/d/graphic/51170.html" rel="external">
          table 3
         </a>
         ). This should be done with close monitoring, since the myoclonus physiology is not confirmed. As examples, a cortical myoclonus physiology may be presumed in a child with Unverricht-Lundborg disease confirmed by genetic testing (cystatin B [
         <em>
          CSTB
         </em>
         ] mutation) and in an adult with Creutzfeldt-Jakob disease who cannot cooperate with electrophysiology testing.
        </p>
        <p>
         When both the specific etiology and myoclonus physiology are uncertain, treatments that have evidence of effectiveness for cortical myoclonus can be tried first, since a cortical physiology is the most common mechanism for myoclonus. (See
         <a class="local">
          'Cortical myoclonus'
         </a>
         below.)
        </p>
        <p>
         An approach to symptomatic treatment of each physiologic/anatomic type of myoclonus is presented in the sections that follow.
        </p>
        <p class="headingAnchor" id="H879818493">
         <span class="h1">
          CORTICAL MYOCLONUS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cortical myoclonus is probably the most commonly encountered type of myoclonus in hospital settings and in cases of new-onset myoclonus in adults. Most cases of symptomatic myoclonus represent cortical myoclonus, including those associated with posthypoxic injury, toxic/metabolic derangements, inflammatory/infectious processes, and neurodegeneration  (
         <a class="graphic graphic_table graphicRef62397" href="/z/d/graphic/62397.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3080935292">
         <span class="h2">
          First-line therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Symptomatic treatment is primarily aimed at suppressing cortical hyperexcitability with antiseizure medications. Among antiseizure medications,
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          levetiracetam
         </a>
         (and piracetam outside the United States),
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          clonazepam
         </a>
         ,
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         , and
         <a class="drug drug_general" data-topicid="87037" href="/z/d/drug information/87037.html" rel="external">
          perampanel
         </a>
         seem to be the most effective for cortical myoclonus. However, there is no singularly effective drug, and treatment often proceeds sequentially using a trial-and-error approach.
        </p>
        <p class="headingAnchor" id="H2199958597">
         <span class="h3">
          Levetiracetam
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          levetiracetam
         </a>
         as initial therapy for most patients with cortical myoclonus. Although no trials have compared various drugs head to head, clinical experience suggests that levetiracetam may work the best, and it tends to be well tolerated and has fewer drug interactions relative to
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          clonazepam
         </a>
         and
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         .
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          Levetiracetam
         </a>
         a broad-spectrum antiseizure medication that binds to the synaptic vesicle protein 2A (SV2A) receptor. Its antimyoclonus effect may be related to modulation of calcium ion channels [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         –
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          Levetiracetam
         </a>
         is initiated at 500 to 1000 mg daily given in two divided doses. It can be titrated up by 1000 mg every two weeks as needed, up to 3000 mg daily. If it is well tolerated and the response is suboptimal, a maximum daily dose of 4000 mg can be tried. Therapeutic levetiracetam doses for myoclonus usually range between 1000 to 3000 mg daily.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Side effects
         </strong>
         – The most common adverse events associated with
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          levetiracetam
         </a>
         are fatigue, somnolence, and dizziness. Most adverse events are mild to moderate in intensity and typically occur during the initial titration phase  (
         <a class="graphic graphic_table graphicRef59755 graphicRef78896" href="/z/d/graphic/59755.html" rel="external">
          table 4A-B
         </a>
         ). Mood and behavioral disturbances may be the most common adverse effects leading to discontinuation of therapy, particularly in children. Abrupt withdrawal of levetiracetam may precipitate seizures or worsening of myoclonus.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Limited evidence from small open-label studies [
         <a href="#rid3">
          3-5
         </a>
         ], case series [
         <a href="#rid6">
          6-9
         </a>
         ], and case reports [
         <a href="#rid10">
          10-14
         </a>
         ] suggests that
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          levetiracetam
         </a>
         is effective or partially effective for various causes of cortical myoclonus. Patients treated in these studies included those with progressive myoclonic epilepsy and progressive myoclonic ataxia syndromes (due to Unverricht-Lundborg disease, Lafora disease, and myoclonus epilepsy with red ragged fibers), benign adult familial myoclonic epilepsy, asterixis (ie, negative myoclonus), posthypoxic myoclonus, Creutzfeldt-Jakob disease, and corticobasal degeneration.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The best-designed of these uncontrolled studies was an open-label evaluation of add-on
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          levetiracetam
         </a>
         (mean dose 3214 mg daily after titration phase) for the treatment of chronic refractory cortical myoclonus [
         <a href="#rid5">
          5
         </a>
         ]. Compared with the pretreatment phase, all 14 patients who completed the study had significant improvement in myoclonus, as assessed by the Unified Myoclonus Rating Scale (UMRS). However, there was no significant change in the negative myoclonus (asterixis) scores of the UMRS.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H817146632">
         <span class="h3">
          Piracetam (outside the US)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Piracetam is an SV2A receptor antagonist that is structurally related to
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          levetiracetam
         </a>
         . It is available in Europe and elsewhere as an antimyoclonus agent and for treatment of cognitive impairment. Although it is marketed as a nutritional supplement in the United States, this formulation is not recommended for treatment of myoclonus due to gastrointestinal side effects and lack of evidence that it is superior to other antimyoclonus agents.
        </p>
        <p>
         Where available as a prescription medication, piracetam is usually started at 2.4 g daily, given in three divided doses. Therapeutic doses of piracetam range between 2.4 to 24 g daily [
         <a href="#rid15">
          15-18
         </a>
         ]. Abrupt discontinuation of piracetam should be avoided since it may precipitate myoclonus exacerbation and/or seizures.
        </p>
        <p>
         A few small controlled studies have found that piracetam is beneficial for cortical myoclonus [
         <a href="#rid15">
          15-18
         </a>
         ]. As an example, a six-week randomized double-blind crossover trial involving 20 adults with Unverricht-Lundborg disease, a cause of progressive myoclonic ataxia, reported that the highest dose of piracetam (total of 24 g daily given in two divided doses) was significantly more effective than placebo for improvement in the primary outcome measure (the mean sum score of six components of a myoclonus rating scale) [
         <a href="#rid17">
          17
         </a>
         ]. The improvement was considered clinically relevant. Lower doses of piracetam (total daily doses of 16.8 and 9.6 g) were associated with a nonsignificant improvement in the primary outcome measure.
        </p>
        <p class="headingAnchor" id="H2758540382">
         <span class="h2">
          Alternatives and add-on therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          Clonazepam
         </a>
         ,
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         , and
         <a class="drug drug_general" data-topicid="87037" href="/z/d/drug information/87037.html" rel="external">
          perampanel
         </a>
         are reasonable first-line alternatives to
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          levetiracetam
         </a>
         or can be used as add-on therapy. The choice among these medications depends largely on side effect profiles and patient comorbidities.
        </p>
        <p>
         Many patients require more than one medication to gain adequate relief from myoclonus [
         <a href="#rid19">
          19
         </a>
         ]. Any of the four first-line medications (
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          levetiracetam
         </a>
         ,
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          clonazepam
         </a>
         ,
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         , and
         <a class="drug drug_general" data-topicid="87037" href="/z/d/drug information/87037.html" rel="external">
          perampanel
         </a>
         ) can be used together or combined with other second-line medications. (See
         <a class="local">
          'Others'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H696967662">
         <span class="h3">
          Clonazepam
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          Clonazepam
         </a>
         has a longer duration of action compared with other benzodiazepines, which is its main advantage when treating myoclonus or seizures. For patients with acute hypoxic myoclonus who are intubated and sedated, intravenous benzodiazepines are more commonly used. (See
         <a class="medical medical_review" href="/z/d/html/127223.html" rel="external">
          "Intensive care unit management of the intubated post-cardiac arrest adult patient", section on 'Myoclonic jerks'
         </a>
         .)
        </p>
        <p>
         The possible mechanism of action of benzodiazepines for myoclonus is facilitation of gamma-aminobutyric acid (GABA) signaling and a decrease in 5-hydroxytryptophan utilization in the brain [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         –
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          Clonazepam
         </a>
         is typically started at 0.25 mg twice daily and gradually increased to a total daily dose of 1.5 to 3 mg given in two to three divided doses. Clonazepam doses ranging from 6 to as high as 12 mg daily are often necessary but should be introduced slowly [
         <a href="#rid19">
          19,20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Side effects
         </strong>
         – The most common side effects of
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          clonazepam
         </a>
         are drowsiness, dizziness, fatigue, and sedation. These can sometimes be ameliorated by adjusting the dose. Abrupt reductions or withdrawals of clonazepam can cause both an exacerbation of myoclonus and withdrawal seizures. As with other benzodiazepines, clonazepam may produce physical and psychologic dependence. In addition, tolerance with loss of effectiveness may develop over a period of several months in some patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – The benefit of
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          clonazepam
         </a>
         for cortical myoclonus is supported by data from uncontrolled observational studies and clinical experience [
         <a href="#rid19">
          19-21
         </a>
         ]. Response rates from controlled studies are not available; in the author's experience, clonazepam is helpful in suppressing myoclonus in 50 percent or more of patients.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2052490991">
         <span class="h3">
          Valproic acid
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          Valproic acid
         </a>
         (valproate) likely acts to suppress myoclonus through multiple mechanisms, including increased GABA synthesis in nerve terminals and decreased GABA degradation in the synapse [
         <a href="#rid1">
          1
         </a>
         ]. It may also reduce excitability by blocking sodium and potassium conductance.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         –
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          Valproate
         </a>
         is introduced slowly, starting at 15 mg/kg daily in three divided doses. It may be increased by 5 to 10 mg/kg per day every week as needed. Therapeutic doses are typically in the range of 1200 to 2000 mg daily. Monitoring and serum target levels are the same as when using valproate as an antiseizure medication. (See
         <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">
          "Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Valproate'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Side effects
         </strong>
         – During initial treatment with
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         , transient gastrointestinal upset may occur, sometimes with nausea and vomiting, and less often with abdominal pain and diarrhea. Other side effects of valproate include weight gain, obesity, hair loss, easy bruising, and tremor  (
         <a class="graphic graphic_table graphicRef59755 graphicRef78896" href="/z/d/graphic/59755.html" rel="external">
          table 4A-B
         </a>
         ). Rare side effects include agranulocytosis, Stevens-Johnson syndrome, aplastic anemia, hepatic failure, dermatitis/rash, serum sickness, and pancreatitis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Evidence from uncontrolled observational studies suggests that
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         is effective for cortical myoclonus due to various underlying causes [
         <a href="#rid19">
          19-22
         </a>
         ], and randomized trials support its efficacy for generalized epilepsy syndromes, with or without cortical-subcortical myoclonus [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3526577043">
         <span class="h3">
          Perampanel
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="87037" href="/z/d/drug information/87037.html" rel="external">
          Perampanel
         </a>
         is an alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor antagonist used for treatment of both focal and generalized epilepsies. It may suppress myoclonus through reduction of cortical hyperexcitability and hypersynchronization [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         Supporting evidence of clinical activity includes case reports and case series in up to 18 patients with seizures and cortical myoclonus of various etiologies [
         <a href="#rid24">
          24-27
         </a>
         ]. In the largest case series, the mean dose was 3.2 mg per day. Dosing is the same as for seizure disorders, with a maximum daily dose of 12 mg. (See
         <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">
          "Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Perampanel'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H883596312">
         <span class="h3">
          Others
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other antiseizure medications for which at least some evidence suggests a potential role in suppressing cortical myoclonus include
         <a class="drug drug_general" data-topicid="106990" href="/z/d/drug information/106990.html" rel="external">
          brivaracetam
         </a>
         ,
         <a class="drug drug_general" data-topicid="9862" href="/z/d/drug information/9862.html" rel="external">
          zonisamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">
          primidone
         </a>
         , and
         <a class="drug drug_general" data-topicid="10268" href="/z/d/drug information/10268.html" rel="external">
          lacosamide
         </a>
         [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="106990" href="/z/d/drug information/106990.html" rel="external">
          Brivaracetam
         </a>
         – Brivaracetam has a similar mechanism of action as
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          levetiracetam
         </a>
         and has shown the ability to suppress cortical myoclonus in animal models; however, clinical data are not as convincing. In two randomized trials in patients with Unverricht-Lundborg disease (cortical myoclonus), doses of 50 to 150 mg per day did not show statistically significant differences compared with placebo [
         <a href="#rid28">
          28
         </a>
         ]. Dosing and adverse effects are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">
          "Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Brivaracetam'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9862" href="/z/d/drug information/9862.html" rel="external">
          Zonisamide
         </a>
         – Zonisamide is a broad-spectrum antiseizure medication that blocks voltage-dependent sodium and T-type calcium channels. Limited data suggest zonisamide may be beneficial as adjunctive therapy for cortical myoclonus at doses ranging from 100 to 300 mg daily [
         <a href="#rid29">
          29,30
         </a>
         ], as well as for other types of myoclonus. (See
         <a class="local">
          'Zonisamide'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">
          Primidone
         </a>
         – Primidone is a
         <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">
          phenobarbital
         </a>
         precursor with GABAergic properties. Limited data suggest some efficacy in treating cortical myoclonus using relatively high doses (eg, 500 to 1500 mg per day) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10268" href="/z/d/drug information/10268.html" rel="external">
          Lacosamide
         </a>
         – Lacosamide is a broad-spectrum antiseizure medication with multiple potential mechanisms of action, including effects on voltage-dependent sodium channels. At least one case report describes response to lacosamide in a patient with posthypoxic myoclonus [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3580687398">
         <span class="h2">
          Medications to avoid
         </span>
         <span class="headingEndMark">
          —
         </span>
         Certain agents can worsen cortical or cortical-subcortical myoclonus, particularly in progressive myoclonic epilepsy syndromes. These agents include
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">
          oxcarbazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10115" href="/z/d/drug information/10115.html" rel="external">
          vigabatrin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10144" href="/z/d/drug information/10144.html" rel="external">
          tiagabine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2162885297">
         <span class="h2">
          Options for refractory symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Treatment of cortical myoclonus is challenging, and polytherapy is often required for optimal symptom control. Gait disturbance tends to be the feature of myoclonus that is most resistant to treatment. A bouncy, unsteady gait with frequent falls may persist despite better control of action and reflex myoclonus in the upper limbs. In addition, there is no consistent evidence that any of the available agents are beneficial for negative myoclonus (asterixis). However, asterixis can have a potentially reversible etiology and will respond to such treatment (eg, correction of metabolic derangement, removal of offending medication).
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8817" href="/z/d/drug information/8817.html" rel="external">
          Sodium oxybate
         </a>
         , the sodium salt form of gamma hydroxybutyrate, has been used for refractory cortical myoclonus and myoclonus-dystonia [
         <a href="#rid33">
          33
         </a>
         ]. However, sodium oxybate is a restricted drug in the United States that is approved only for the treatment of narcolepsy and idiopathic hypersomnia. (See
         <a class="medical medical_review" href="/z/d/html/7681.html" rel="external">
          "Treatment of narcolepsy in adults", section on 'Oxybates'
         </a>
         .)
        </p>
        <p>
         Intrathecal
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         has been tried in a few cases of posthypoxic myoclonus that was refractory to other therapies [
         <a href="#rid34">
          34,35
         </a>
         ]. At baclofen doses of 75 to 105 micrograms per hour, both the resting and action myoclonus were controlled. In another report, two cases of spinal myoclonus had marked response to this therapy [
         <a href="#rid36">
          36
         </a>
         ]. Further examples are needed for verification.
        </p>
        <p>
         Repetitive transcranial magnetic stimulation (rTMS) has been used rarely for cases of either cortical or subcortical myoclonus [
         <a href="#rid37">
          37
         </a>
         ]. More studies are needed before this therapy can be applied regularly.
        </p>
        <p>
         In refractory cases of posthypoxic myoclonus, deep brain stimulation (DBS) may offer some chance of benefit. Responses have been reported with a variety of stimulation targets, including bilateral globus pallidus interna (GPi), bilateral ventral intermediate (VIM) nucleus of the thalamus, and subthalamic nucleus/pars reticulata [
         <a href="#rid38">
          38-40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4144058941">
         <span class="h1">
          CORTICAL-SUBCORTICAL MYOCLONUS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The myoclonus in patients with primary generalized epilepsy syndromes falls under the cortical-subcortical physiologic classification  (
         <a class="graphic graphic_table graphicRef62397" href="/z/d/graphic/62397.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid41">
          41
         </a>
         ]. The treatment of these disorders is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/17192.html" rel="external">
          "Juvenile myoclonic epilepsy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6162.html" rel="external">
          "Epilepsy syndromes in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3468677091">
         <span class="h1">
          SUBCORTICAL-NONSEGMENTAL MYOCLONUS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Subcortical-nonsegmental myoclonus is a heterogeneous entity that includes rare entities such as essential myoclonus, myoclonus-dystonia syndrome, reflex myoclonus, hyperekplexia, and propriospinal myoclonus.
        </p>
        <p>
         Standard antiseizure medications such as
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          levetiracetam
         </a>
         and
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         are usually
         <strong>
          not
         </strong>
         helpful in most types of subcortical-nonsegmental myoclonus  (
         <a class="graphic graphic_table graphicRef62397" href="/z/d/graphic/62397.html" rel="external">
          table 2
         </a>
         ).
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          Clonazepam
         </a>
         is a good first choice, based on clinical experience and largely anecdotal evidence.
        </p>
        <p class="headingAnchor" id="H683174563">
         <span class="h2">
          Clonazepam
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest initial treatment with
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          clonazepam
         </a>
         for most patients with subcortical-nonsegmental myoclonus physiology. Dosing is the same as described for cortical myoclonus. (See
         <a class="local">
          'Clonazepam'
         </a>
         above.)
        </p>
        <p>
         Supporting evidence includes case series in patients with essential myoclonus [
         <a href="#rid42">
          42
         </a>
         ], myoclonus-dystonia, reticular reflex myoclonus [
         <a href="#rid21">
          21
         </a>
         ], hyperekplexia [
         <a href="#rid43">
          43
         </a>
         ], and propriospinal myoclonus [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H832803869">
         <span class="h2">
          Zonisamide
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9862" href="/z/d/drug information/9862.html" rel="external">
          Zonisamide
         </a>
         is an alternative for myoclonus-dystonia and should be tried if there is insufficient improvement with
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          clonazepam
         </a>
         .
        </p>
        <p>
         A single-center, placebo-controlled, randomized crossover trial of 24 patients with myoclonus-dystonia found that
         <a class="drug drug_general" data-topicid="9862" href="/z/d/drug information/9862.html" rel="external">
          zonisamide
         </a>
         (starting at 50 mg daily and titrating up to a maximum dose of 300 mg daily) led to significant improvement in action myoclonus and functional disability [
         <a href="#rid45">
          45
         </a>
         ]. Limited data also suggest zonisamide may be beneficial for propriospinal myoclonus [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1352075087">
         <span class="h2">
          Others
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9106" href="/z/d/drug information/9106.html" rel="external">
          Benztropine
         </a>
         or
         <a class="drug drug_general" data-topicid="10022" href="/z/d/drug information/10022.html" rel="external">
          trihexyphenidyl
         </a>
         are alternate choices for initial or add-on therapy for patients with essential myoclonus, including myoclonus-dystonia [
         <a href="#rid47">
          47,48
         </a>
         ]. Responses to
         <a class="drug drug_general" data-topicid="8817" href="/z/d/drug information/8817.html" rel="external">
          sodium oxybate
         </a>
         , the sodium salt of gamma hydroxybutyrate, have been described in patients with essential myoclonus, and further studies seem warranted [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
         For propriospinal myoclonus, there are case reports of responses to
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          levetiracetam
         </a>
         ,
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">
          oxcarbazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         [
         <a href="#rid1">
          1,49
         </a>
         ].
        </p>
        <p>
         Of note, essential myoclonus (including myoclonus-dystonia) tends to be responsive to alcohol, similar to the effect seen in essential tremor. Some patients self-medicate and should be monitored for unhealthy or excessive alcohol use.
        </p>
        <p class="headingAnchor" id="H3659014675">
         <span class="h2">
          Role of surgical therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Select patients with refractory myoclonus-dystonia syndrome may be candidates for deep brain stimulation (DBS) [
         <a href="#rid50">
          50
         </a>
         ]. It should be considered only for refractory cases with significant disability.
        </p>
        <p>
         A systematic review identified 40 unique patients with myoclonus-dystonia syndrome treated with DBS with a mean follow-up of 27 months and noted that all patients improved with treatment; the mean improvement in myoclonus scores was 73 percent, and the mean improvement in dystonia scores was 53 percent [
         <a href="#rid51">
          51
         </a>
         ]. The degree of improvement in myoclonus was similar for stimulation of both the globus pallidus interna (GPi) and ventral intermediate nucleus of the thalamus (VIM; 76 and 70 percent, respectively). However, improvement in dystonia was greater with GPi stimulation compared with VIM stimulation (60 and 33 percent, respectively).
        </p>
        <p>
         These findings suggest that GPi is the preferred DBS target for myoclonus-dystonia syndrome. However, the results should be interpreted with caution since the data come from retrospective and nonrandomized reports. Moreover, myoclonus-dystonia syndrome has different causes, and treatment response may vary depending on etiology; most of the studies suggesting the benefit of DBS have evaluated patients with myoclonus-dystonia syndrome (DYT11) caused by sarcoglycan epsilon (
         <em>
          SGCE
         </em>
         ) gene mutations, which is the most commonly identified cause of myoclonus-dystonia [
         <a href="#rid52">
          52
         </a>
         ]. DBS for dystonia is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/4887.html" rel="external">
          "Treatment of dystonia in children and adults", section on 'Surgical therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H410741557">
         <span class="h1">
          SEGMENTAL OR PERIPHERAL MYOCLONUS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common types of segmental myoclonus are palatal myoclonus and segmental spinal myoclonus. Hemifacial spasm is the main example of peripheral myoclonus. Based on their localized nature, botulinum toxin injections are an alternative option to oral medication trials in selected patients.
        </p>
        <p class="headingAnchor" id="H553354548">
         <span class="h2">
          Palatal myoclonus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Palatal myoclonus is difficult to treat [
         <a href="#rid53">
          53
         </a>
         ]. For most patients with debilitating symptoms, we suggest botulinum toxin injections as initial treatment. The injections should be performed by a practitioner (often an otolaryngologist) or center with sufficient expertise in the anatomic area.
        </p>
        <p>
         The target muscles for injection of botulinum toxin are the levator veli palatini and/or tensor veli palatini muscles [
         <a href="#rid54">
          54-56
         </a>
         ]. In the largest case series, botulinum toxin injections were associated with complete resolution of symptoms (objective, intrusive clicking tinnitus) in four of five treated patients [
         <a href="#rid55">
          55
         </a>
         ]. One patient had transient side effects that included dysphagia and nasal speech.
        </p>
        <p>
         Other pharmacologic interventions for palatal myoclonus generally provide only limited benefit, or more commonly no benefit. However, the list of possibly useful drugs for this condition includes
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          clonazepam
         </a>
         [
         <a href="#rid57">
          57
         </a>
         ], piracetam,
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         ,
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9968" href="/z/d/drug information/9968.html" rel="external">
          sumatriptan
         </a>
         [
         <a href="#rid57">
          57,58
         </a>
         ], and
         <a class="drug drug_general" data-topicid="9476" href="/z/d/drug information/9476.html" rel="external">
          tetrabenazine
         </a>
         .
        </p>
        <p>
         Because the ear clicking associated with palatal myoclonus is so disabling, surgical treatments including tensor veli palatini tenotomy and occlusion of the eustachian tube can be considered for patients refractory to pharmacologic therapy (including botulinum toxin injection) [
         <a href="#rid59">
          59
         </a>
         ]. Surgical interventions for middle ear myoclonus include tensor tympani and/or stapedius tenotomy and placement of ventilation tubes [
         <a href="#rid60">
          60-63
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H715777558">
         <span class="h2">
          Spinal segmental myoclonus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Like palatal myoclonus, spinal segmental myoclonus is often difficult to treat and not very responsive to oral medications. If the underlying cause is a structural abnormality such as a thoracic disc herniation, appropriate surgery can alleviate symptoms [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
         Among oral medications,
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          clonazepam
         </a>
         is most commonly used; doses of up to 6 mg daily may be needed [
         <a href="#rid21">
          21,53,65
         </a>
         ]. However, benefit is often limited. Other medications with possible benefit include
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          levetiracetam
         </a>
         [
         <a href="#rid66">
          66
         </a>
         ],
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         [
         <a href="#rid49">
          49
         </a>
         ],
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         [
         <a href="#rid67">
          67
         </a>
         ],
         <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">
          topiramate
         </a>
         [
         <a href="#rid68">
          68
         </a>
         ],
         <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">
          diazepam
         </a>
         , and
         <a class="drug drug_general" data-topicid="9476" href="/z/d/drug information/9476.html" rel="external">
          tetrabenazine
         </a>
         [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
         There are a few reports of some success with botulinum toxin injections for the pain and movements of spinal segmental myoclonus [
         <a href="#rid69">
          69,70
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1370727036">
         <span class="h2">
          Hemifacial spasm
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest botulinum toxin injections for patients with disabling hemifacial spasm and other types of peripheral myoclonus. The botulinum toxin usually treats the faster phasic (myoclonus) movements as well as more tonic movements (spasm). It should be administered by clinicians with expertise in treating these disorders [
         <a href="#rid71">
          71-74
         </a>
         ].
        </p>
        <p>
         In a randomized controlled trial, 11 patients with hemifacial spasm were randomly cycled through four treatment arms, which consisted of three different doses of botulinum toxin injection and one
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         placebo injection [
         <a href="#rid75">
          75
         </a>
         ]. There was objective improvement in symptoms after 84 percent of botulinum toxin injections versus 0 percent of placebo injections. Facial weakness was an expected side effect and was observed after 97 percent of botulinum toxin injections. Facial bruising, diplopia, and ptosis occurred after 20, 13, and 7 percent of injections, respectively. In another small trial, the mean duration of benefit after botulinum toxin injection for hemifacial spasm was 16.5 weeks [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
         Oral medications for peripheral myoclonus are usually ineffective, but
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         may have some effect [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
         Microvascular decompression is an option for patients with severe hemifacial spasm. In a retrospective review of 5685 patients treated with microvascular decompression for hemifacial spasm, there was complete resolution of symptoms over a median three-year follow-up in 91 percent [
         <a href="#rid77">
          77
         </a>
         ]. Complications included transient facial palsy in 10 percent, permanent facial palsy in 1 percent, permanent hearing loss in 2 percent, and stroke and death in &lt;0.1 percent each.
        </p>
        <p class="headingAnchor" id="H286743860">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/82945.html" rel="external">
          "Patient education: Myoclonus (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General principles
         </strong>
         – There are myriad etiologies  (
         <a class="graphic graphic_table graphicRef78331" href="/z/d/graphic/78331.html" rel="external">
          table 1
         </a>
         ) and multiple anatomic/physiologic types of myoclonus  (
         <a class="graphic graphic_table graphicRef62397" href="/z/d/graphic/62397.html" rel="external">
          table 2
         </a>
         ). Both elements of classification help to guide therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Treat the underlying disorder
         </strong>
         – Certain types of myoclonus can be partially or totally reversed by treating the underlying condition. Examples include myoclonus due to an acquired metabolic abnormality, a medication or toxin, or an excisable lesion. (See
         <a class="local">
          'Treat the underlying disorder'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Decide whether symptomatic therapy is indicated
         </strong>
         – There is no singularly effective therapy for myoclonus, and benefits and side effects may be closely matched. Symptomatic treatment is typically indicated for patients with significant disability related to the myoclonus, whether physical or social, or when myoclonus causes high levels of distress to family and caretakers. (See
         <a class="local">
          'Assess need for symptomatic therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptomatic therapy
         </strong>
         – Symptomatic treatment of myoclonus is guided by the anatomic/physiologic type, of which there are five major groups: cortical, cortical-subcortical, subcortical-nonsegmental, segmental, and peripheral  (
         <a class="graphic graphic_table graphicRef62397" href="/z/d/graphic/62397.html" rel="external">
          table 2
         </a>
         ). In cases when the etiology and myoclonus physiology are uncertain, it is reasonable to follow guidance for cortical myoclonus.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cortical myoclonus
         </strong>
         –
         <strong>
         </strong>
         For patients with debilitating cortical myoclonus, we suggest
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          levetiracetam
         </a>
         as initial therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Piracetam (outside the United States),
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          clonazepam
         </a>
         ,
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         , and
         <a class="drug drug_general" data-topicid="87037" href="/z/d/drug information/87037.html" rel="external">
          perampanel
         </a>
         are reasonable alternatives for initial or add-on therapy. (See
         <a class="local">
          'Cortical myoclonus'
         </a>
         above and
         <a class="local">
          'Levetiracetam'
         </a>
         above and
         <a class="local">
          'Piracetam (outside the US)'
         </a>
         above and
         <a class="local">
          'Clonazepam'
         </a>
         above and
         <a class="local">
          'Valproic acid'
         </a>
         above and
         <a class="local">
          'Perampanel'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Certain antiseizure medications can worsen cortical or cortical-subcortical myoclonus, particularly in progressive myoclonic epilepsy syndromes. These agents include
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">
          oxcarbazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10115" href="/z/d/drug information/10115.html" rel="external">
          vigabatrin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10144" href="/z/d/drug information/10144.html" rel="external">
          tiagabine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         . (See
         <a class="local">
          'Medications to avoid'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cortical-subcortical myoclonus
         </strong>
         – Cortical-subcortical myoclonus occurs primarily in association with generalized epilepsy syndromes  (
         <a class="graphic graphic_table graphicRef62397" href="/z/d/graphic/62397.html" rel="external">
          table 2
         </a>
         ). The treatment of these disorders is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/17192.html" rel="external">
          "Juvenile myoclonic epilepsy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6162.html" rel="external">
          "Epilepsy syndromes in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Subcortical-nonsegmental myoclonus
         </strong>
         – For patients with subcortical-nonsegmental myoclonus (eg, essential myoclonus, myoclonus-dystonia syndrome, reticular reflex myoclonus, hyperekplexia, or propriospinal myoclonus), we suggest initial treatment with
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          clonazepam
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
         <a class="drug drug_general" data-topicid="9862" href="/z/d/drug information/9862.html" rel="external">
          Zonisamide
         </a>
         is an alternative for myoclonus-dystonia and should be tried if there is insufficient improvement with clonazepam.
         <a class="drug drug_general" data-topicid="9106" href="/z/d/drug information/9106.html" rel="external">
          Benztropine
         </a>
         and
         <a class="drug drug_general" data-topicid="10022" href="/z/d/drug information/10022.html" rel="external">
          trihexyphenidyl
         </a>
         are additional options for essential myoclonus. (See
         <a class="local">
          'Subcortical-nonsegmental myoclonus'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Palatal myoclonus
         </strong>
         – Palatal myoclonus is typically refractory to oral medications and can be debilitating, most commonly from the clicking noise that it creates. For debilitating palatal myoclonus, we suggest treatment with botulinum toxin injections (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Injections are typically administered by an otolaryngologist with experience in treating myoclonus. (See
         <a class="local">
          'Palatal myoclonus'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Spinal segmental myoclonus
         </strong>
         – For spinal segmental myoclonus, we suggest
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          clonazepam
         </a>
         as initial treatment (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Botulinum toxin injections are sometimes helpful as an alternative. (See
         <a class="local">
          'Spinal segmental myoclonus'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hemifacial spasm
         </strong>
         – For most patients with disabling hemifacial spasm, we suggest treatment with botulinum toxin injections rather than oral medications (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Injections should be performed by a practitioner or center with the necessary anatomic and technical expertise. (See
         <a class="local">
          'Hemifacial spasm'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Pena AB, Caviness JN. Physiology-Based Treatment of Myoclonus. Neurotherapeutics 2020; 17:1665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caviness JN. Myoclonus. Continuum (Minneap Minn) 2019; 25:1055.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crest C, Dupont S, Leguern E, et al. Levetiracetam in progressive myoclonic epilepsy: an exploratory study in 9 patients. Neurology 2004; 62:640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim LL, Ahmed A. Limited efficacy of levetiracetam on myoclonus of different etiologies. Parkinsonism Relat Disord 2005; 11:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Striano P, Manganelli F, Boccella P, et al. Levetiracetam in patients with cortical myoclonus: a clinical and electrophysiological study. Mov Disord 2005; 20:1610.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Genton P, Gélisse P. Antimyoclonic effect of levetiracetam. Epileptic Disord 2000; 2:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krauss GL, Bergin A, Kramer RE, et al. Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam. Neurology 2001; 56:411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frucht SJ, Louis ED, Chuang C, Fahn S. A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology 2001; 57:1112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magaudda A, Gelisse P, Genton P. Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-Lundborg disease: clinical observations. Epilepsia 2004; 45:678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gelisse P, Crespel A, Genton P, Baldy-Moulinier M. Dramatic effect of levetiracetam on epileptic negative myoclonus. Acta Neurol Scand 2003; 107:302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Imperiale D, Bortolotto S, Cucatto A, et al. Levetiracetam control of myoclonus in a patient with Creutzfeldt-Jakob disease. Eur Neurol 2003; 49:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mancuso M, Galli R, Pizzanelli C, et al. Antimyoclonic effect of levetiracetam in MERRF syndrome. J Neurol Sci 2006; 243:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kinrions P, Ibrahim N, Murphy K, et al. Efficacy of levetiracetam in a patient with Unverricht-Lundborg progressive myoclonic epilepsy. Neurology 2003; 60:1394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cho JW, Lee JH. Suppression of myoclonus in corticobasal degeneration by levetiracetam. J Mov Disord 2014; 7:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown P, Steiger MJ, Thompson PD, et al. Effectiveness of piracetam in cortical myoclonus. Mov Disord 1993; 8:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ikeda A, Shibasaki H, Tashiro K, et al. Clinical trial of piracetam in patients with myoclonus: nationwide multiinstitution study in Japan. The Myoclonus/Piracetam Study Group. Mov Disord 1996; 11:691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koskiniemi M, Van Vleymen B, Hakamies L, et al. Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo. J Neurol Neurosurg Psychiatry 1998; 64:344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fedi M, Reutens D, Dubeau F, et al. Long-term efficacy and safety of piracetam in the treatment of progressive myoclonus epilepsy. Arch Neurol 2001; 58:781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Obeso JA, Artieda J, Rothwell JC, et al. The treatment of severe action myoclonus. Brain 1989; 112 ( Pt 3):765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caviness JN. Treatment of myoclonus. Neurotherapeutics 2014; 11:188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Obeso JA. Therapy of myoclonus. Clin Neurosci 1995-1996; 3:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fahn S. Posthypoxic action myoclonus: review of the literature and report of two new cases with response to valproate and estrogen. Adv Neurol 1979; 26:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nevitt SJ, Sudell M, Weston J, et al. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database Syst Rev 2017; 6:CD011412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oi K, Neshige S, Hitomi T, et al. Low-dose perampanel improves refractory cortical myoclonus by the dispersed and suppressed paroxysmal depolarization shifts in the sensorimotor cortex. Clin Neurophysiol 2019; 130:1804.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santamarina E, Sueiras M, Lidón RM, et al. Use of perampanel in one case of super-refractory hypoxic myoclonic status: Case report. Epilepsy Behav Case Rep 2015; 4:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steinhoff BJ, Bacher M, Kurth C, et al. Add-on perampanel in Lance-Adams syndrome. Epilepsy Behav Case Rep 2016; 6:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bianchini S, Bellantoni G, Albergati A, Magrassi L. Postsurgical cortical myoclonus responsive to perampanel. Neurol Clin Pract 2018; 8:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kälviäinen R, Genton P, Andermann E, et al. Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies. Epilepsia 2016; 57:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kyllerman M, Ben-Menachem E. Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients. Epilepsy Res 1998; 29:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoshimura I, Kaneko S, Yoshimura N, Murakami T. Long-term observations of two siblings with Lafora disease treated with zonisamide. Epilepsy Res 2001; 46:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galldiks N, Timmermann L, Fink GR, Burghaus L. Posthypoxic myoclonus (Lance-Adams syndrome) treated with lacosamide. Clin Neuropharmacol 2010; 33:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michelucci R, Pasini E, Riguzzi P, et al. Myoclonus and seizures in progressive myoclonus epilepsies: pharmacology and therapeutic trials. Epileptic Disord 2016; 18:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frucht SJ, Houghton WC, Bordelon Y, et al. A single-blind, open-label trial of sodium oxybate for myoclonus and essential tremor. Neurology 2005; 65:1967.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Birthi P, Walters C, Ortiz Vargas O, Karandikar N. The use of intrathecal baclofen therapy for myoclonus in a patient with Lance Adams syndrome. PM R 2011; 3:671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whitlock JA Jr, Dumigan RW. Treatment of Postanoxic Action Myoclonus With Intrathecal Baclofen: A Case Report. PM R 2018; 10:870.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiodo AE, Saval A. Intrathecal baclofen for the treatment of spinal myoclonus: a case series. J Spinal Cord Med 2012; 35:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nardone R, Versace V, Höller Y, et al. Transcranial magnetic stimulation in myoclonus of different aetiologies. Brain Res Bull 2018; 140:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asahi T, Kashiwazaki D, Dougu N, et al. Alleviation of myoclonus after bilateral pallidal deep brain stimulation for Lance-Adams syndrome. J Neurol 2015; 262:1581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramdhani RA, Frucht SJ, Kopell BH. Improvement of Post-hypoxic Myoclonus with Bilateral Pallidal Deep Brain Stimulation: A Case Report and Review of the Literature. Tremor Other Hyperkinet Mov (N Y) 2017; 7:461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kobayashi K, Katayama Y, Otaka T, et al. Thalamic deep brain stimulation for the treatment of action myoclonus caused by perinatal anoxia. Stereotact Funct Neurosurg 2010; 88:259.
          </a>
         </li>
         <li class="breakAll">
          Caviness JN. Epileptic myoclonus. In: Atlas of Video-EEG Monitoring, Sirven JI, Stern JM (Eds), McGraw-Hill Medical, New York 2011. p.309.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bressman S, Fahn S. Essential myoclonus. Adv Neurol 1986; 43:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tijssen MA, Schoemaker HC, Edelbroek PJ, et al. The effects of clonazepam and vigabatrin in hyperekplexia. J Neurol Sci 1997; 149:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montagna P, Provini F, Plazzi G, et al. Propriospinal myoclonus upon relaxation and drowsiness: a cause of severe insomnia. Mov Disord 1997; 12:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hainque E, Vidailhet M, Cozic N, et al. A randomized, controlled, double-blind, crossover trial of zonisamide in myoclonus-dystonia. Neurology 2016; 86:1729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roze E, Bounolleau P, Ducreux D, et al. Propriospinal myoclonus revisited: Clinical, neurophysiologic, and neuroradiologic findings. Neurology 2009; 72:1301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chokroverty S, Manocha MK, Duvoisin RC. A physiologic and pharmacologic study in anticholinergic-responsive essential myoclonus. Neurology 1987; 37:608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duvoisin RC. Essential myoclonus: response to anticholinergic therapy. Clin Neuropharmacol 1984; 7:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uluduz D, Karaali-Savrun F, Gunduz A, Kiziltan ME. An unusual case of vascular loop syndrome. J Headache Pain 2007; 8:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roze E, Vidailhet M, Hubsch C, et al. Pallidal stimulation for myoclonus-dystonia: Ten years' outcome in two patients. Mov Disord 2015; 30:871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rughani AI, Lozano AM. Surgical treatment of myoclonus dystonia syndrome. Mov Disord 2013; 28:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vidailhet M, Jutras MF, Grabli D, Roze E. Deep brain stimulation for dystonia. J Neurol Neurosurg Psychiatry 2013; 84:1029.
          </a>
         </li>
         <li class="breakAll">
          Caviness JN. Segmental myoclonus. In: Hyperkinetic Movement Disorders, Albanese A, Jankovic J (Eds), Wiley-Blackwell, Oxford 2012. p.221.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krause E, Leunig A, Klopstock T, Gürkov R. Treatment of essential palatal myoclonus in a 10-year-old girl with botulinum neurotoxin. Otol Neurotol 2006; 27:672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Penney SE, Bruce IA, Saeed SR. Botulinum toxin is effective and safe for palatal tremor: a report of five cases and a review of the literature. J Neurol 2006; 253:857.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sinclair CF, Gurey LE, Blitzer A. Palatal myoclonus: algorithm for management with botulinum toxin based on clinical disease characteristics. Laryngoscope 2014; 124:1164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fabiani G, Teive HA, Sá D, et al. Palatal myoclonus: report of two cases. Arq Neuropsiquiatr 2000; 58:901.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scott BL, Evans RW, Jankovic J. Treatment of palatal myoclonus with sumatriptan. Mov Disord 1996; 11:748.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ensink RJ, Vingerhoets HM, Schmidt CW, Cremers CW. Treatment for severe palatoclonus by occlusion of the eustachian tube. Otol Neurotol 2003; 24:714.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bento RF, Sanchez TG, Miniti A, Tedesco-Marchesi AJ. Continuous, high-frequency objective tinnitus caused by middle ear myoclonus. Ear Nose Throat J 1998; 77:814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Golz A, Fradis M, Netzer A, et al. Bilateral tinnitus due to middle-ear myoclonus. Int Tinnitus J 2003; 9:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Golz A, Fradis M, Martzu D, et al. Stapedius muscle myoclonus. Ann Otol Rhinol Laryngol 2003; 112:522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhimrao SK, Masterson L, Baguley D. Systematic review of management strategies for middle ear myoclonus. Otolaryngol Head Neck Surg 2012; 146:698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jang W, Kim JS, Ahn JY, Kim HT. Reversible propriospinal myoclonus due to thoracic disc herniation: long-term follow-up. J Neurol Sci 2012; 313:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jankovic J, Pardo R. Segmental myoclonus. Clinical and pharmacologic study. Arch Neurol 1986; 43:1025.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keswani SC, Kossoff EH, Krauss GL, Hagerty C. Amelioration of spinal myoclonus with levetiracetam. J Neurol Neurosurg Psychiatry 2002; 73:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nasr A, Brown N. Palatal myoclonus responding to lamotrigine. Seizure 2002; 11:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siniscalchi A, Mancuso F, Russo E, et al. Spinal myoclonus responsive to topiramate. Mov Disord 2004; 19:1380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lagueny A, Tison F, Burbaud P, et al. Stimulus-sensitive spinal segmental myoclonus improved with injections of botulinum toxin type A. Mov Disord 1999; 14:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campos CR, Limongi JC, Machado FC, Brotto MW. A case of primary spinal myoclonus: clinical presentation and possible mechanisms involved. Arq Neuropsiquiatr 2003; 61:112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simpson DM, Blitzer A, Brashear A, et al. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70:1699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Defazio G, Abbruzzese G, Girlanda P, et al. Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study. Arch Neurol 2002; 59:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kenney C, Jankovic J. Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm (Vienna) 2008; 115:585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carnero-Pardo C, Sánchez-Alvarez JC, Gómez-Camello A, et al. Myoclonus associated with thoracodorsal neuropathy. Mov Disord 1998; 13:971.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoshimura DM, Aminoff MJ, Tami TA, Scott AB. Treatment of hemifacial spasm with botulinum toxin. Muscle Nerve 1992; 15:1045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park YC, Lim JK, Lee DK, Yi SD. Botulinum a toxin treatment of hemifacial spasm and blepharospasm. J Korean Med Sci 1993; 8:334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller LE, Miller VM. Safety and effectiveness of microvascular decompression for treatment of hemifacial spasm: a systematic review. Br J Neurosurg 2012; 26:438.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4888 Version 21.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32910414" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Physiology-Based Treatment of Myoclonus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31356293" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Myoclonus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14981187" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Levetiracetam in progressive myoclonic epilepsy: an exploratory study in 9 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15734675" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Limited efficacy of levetiracetam on myoclonus of different etiologies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16078205" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Levetiracetam in patients with cortical myoclonus: a clinical and electrophysiological study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11174151" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Antimyoclonic effect of levetiracetam.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11171914" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11571347" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15144434" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-Lundborg disease: clinical observations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12675706" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Dramatic effect of levetiracetam on epileptic negative myoclonus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12646771" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Levetiracetam control of myoclonus in a patient with Creutzfeldt-Jakob disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16414077" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Antimyoclonic effect of levetiracetam in MERRF syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12707458" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Efficacy of levetiracetam in a patient with Unverricht-Lundborg progressive myoclonic epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24926409" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Suppression of myoclonus in corticobasal degeneration by levetiracetam.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8419809" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Effectiveness of piracetam in cortical myoclonus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8914096" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Clinical trial of piracetam in patients with myoclonus: nationwide multiinstitution study in Japan. The Myoclonus/Piracetam Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9527146" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11346373" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Long-term efficacy and safety of piracetam in the treatment of progressive myoclonus epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2499399" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : The treatment of severe action myoclonus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24037428" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Treatment of myoclonus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8891399" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Therapy of myoclonus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/229719" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Posthypoxic action myoclonus: review of the literature and report of two new cases with response to valproate and estrogen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28661008" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31401489" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Low-dose perampanel improves refractory cortical myoclonus by the dispersed and suppressed paroxysmal depolarization shifts in the sensorimotor cortex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26286206" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Use of perampanel in one case of super-refractory hypoxic myoclonic status: Case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27437182" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Add-on perampanel in Lance-Adams syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29708211" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Postsurgical cortical myoclonus responsive to perampanel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26666500" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Brivaracetam in Unverricht-Lundborg disease (EPM1): Results from two randomized, double-blind, placebo-controlled studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9477142" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11518630" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Long-term observations of two siblings with Lafora disease treated with zonisamide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20661030" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Posthypoxic myoclonus (Lance-Adams syndrome) treated with lacosamide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27629998" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Myoclonus and seizures in progressive myoclonus epilepsies: pharmacology and therapeutic trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16382538" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : A single-blind, open-label trial of sodium oxybate for myoclonus and essential tremor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21777867" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : The use of intrathecal baclofen therapy for myoclonus in a patient with Lance Adams syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29366919" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Treatment of Postanoxic Action Myoclonus With Intrathecal Baclofen: A Case Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22330193" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Intrathecal baclofen for the treatment of spinal myoclonus: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29803873" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Transcranial magnetic stimulation in myoclonus of different aetiologies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25929661" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Alleviation of myoclonus after bilateral pallidal deep brain stimulation for Lance-Adams syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28616357" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Improvement of Post-hypoxic Myoclonus with Bilateral Pallidal Deep Brain Stimulation: A Case Report and Review of the Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20530980" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Thalamic deep brain stimulation for the treatment of action myoclonus caused by perinatal anoxia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20530980" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Thalamic deep brain stimulation for the treatment of action myoclonus caused by perinatal anoxia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3080850" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Essential myoclonus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9168167" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The effects of clonazepam and vigabatrin in hyperekplexia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8990056" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Propriospinal myoclonus upon relaxation and drowsiness: a cause of severe insomnia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27053715" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : A randomized, controlled, double-blind, crossover trial of zonisamide in myoclonus-dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19365051" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Propriospinal myoclonus revisited: Clinical, neurophysiologic, and neuroradiologic findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3561772" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : A physiologic and pharmacologic study in anticholinergic-responsive essential myoclonus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6733693" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Essential myoclonus: response to anticholinergic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17906834" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : An unusual case of vascular loop syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25787304" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Pallidal stimulation for myoclonus-dystonia: Ten years' outcome in two patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23401150" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Surgical treatment of myoclonus dystonia syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23154125" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Deep brain stimulation for dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23154125" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Deep brain stimulation for dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16868515" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Treatment of essential palatal myoclonus in a 10-year-old girl with botulinum neurotoxin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16845571" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Botulinum toxin is effective and safe for palatal tremor: a report of five cases and a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24668771" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Palatal myoclonus: algorithm for management with botulinum toxin based on clinical disease characteristics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11018829" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Palatal myoclonus: report of two cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8914109" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Treatment of palatal myoclonus with sumatriptan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14501444" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Treatment for severe palatoclonus by occlusion of the eustachian tube.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9818532" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Continuous, high-frequency objective tinnitus caused by middle ear myoclonus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14763331" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Bilateral tinnitus due to middle-ear myoclonus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12834120" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Stapedius muscle myoclonus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22261497" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Systematic review of management strategies for middle ear myoclonus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22014609" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Reversible propriospinal myoclonus due to thoracic disc herniation: long-term follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3753263" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Segmental myoclonus. Clinical and pharmacologic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12235322" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Amelioration of spinal myoclonus with levetiracetam.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11945102" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Palatal myoclonus responding to lamotrigine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15389982" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Spinal myoclonus responsive to topiramate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9918374" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Stimulus-sensitive spinal segmental myoclonus improved with injections of botulinum toxin type A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12715032" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : A case of primary spinal myoclonus: clinical presentation and possible mechanisms involved.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18458230" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11890846" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17558461" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Botulinum toxin in the treatment of blepharospasm and hemifacial spasm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9827626" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Myoclonus associated with thoracodorsal neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1518513" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Treatment of hemifacial spasm with botulinum toxin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8305141" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Botulinum a toxin treatment of hemifacial spasm and blepharospasm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22168965" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Safety and effectiveness of microvascular decompression for treatment of hemifacial spasm: a systematic review.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
